MedStar Authors catalog › Details for: Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma.
Normal view MARC view ISBD view

Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma.

by Narkhede, Mayur; Sarraf Yazdy, Maryam.
Citation: Expert Review of Hematology. 11(10):773-780, 2018 10..Journal: Expert review of hematology.Published: ; 2018ISSN: 1747-4094.Full author list: Narkhede M; Sarraf Yazdy M; Cheson B.UI/PMID: 30139285.Subject(s): *Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use] | Bleomycin/tu [Therapeutic Use] | Dacarbazine/tu [Therapeutic Use] | Doxorubicin/tu [Therapeutic Use] | Female | *Hodgkin Disease/dt [Drug Therapy] | Hodgkin Disease/ep [Epidemiology] | Humans | Immunoconjugates/tu [Therapeutic Use] | Male | Recurrence | United States/ep [Epidemiology] | Vinblastine/tu [Therapeutic Use]Institution(s): MedStar Washington Hospital CenterDepartment(s): Hematology and OncologyActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.1080/17474086.2018.1516135 (Click here) Abbreviated citation: Expert Rev Hematol. 11(10):773-780, 2018 10.Abstract: INTRODUCTION: Hodgkin lymphoma (HL) accounts for about 10% of all lymphomas in the United States. Exceptional progress has been made in the treatment of HL with complete response rates up to 94% in limited stage and 88% in advanced stage disease with regimens such as adriamycin, bleomycin, vinblastine, dacarbazine in the frontline setting. Nevertheless, up to 10% of patients with limited stage disease and 20-30% of those with advanced stage HL relapse. In the last decade, newer agents such as brentuximab vedotin (BV) and checkpoint inhibitors have been approved by the FDA for treatment of patients with relapsed or refractory HL. As these newer agents are increasingly incorporated in both the front-line and relapsed settings, their optimal sequence becomes challenging for clinicians. Areas covered: This review will discuss the evidence behind the approval of BV and checkpoint inhibitors in HL and the appropriate sequence for using them in relapsed Hodgkin lymphoma. Expert Commentary: The appropriate sequence of BV and/or checkpoint inhibitors in the relapsed setting depends on the regimen used in the frontline setting.

Powered by Koha